Vertex Pharmaceuticals (VRTX) EPS (Weighted Average and Diluted) (2016 - 2025)
Historic EPS (Weighted Average and Diluted) for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q3 2025 value amounting to $4.2.
- Vertex Pharmaceuticals' EPS (Weighted Average and Diluted) rose 473.82% to $4.2 in Q3 2025 from the same period last year, while for Sep 2025 it was $14.21, marking a year-over-year increase of 81407.04%. This contributed to the annual value of -$2.08 for FY2024, which is 11494.64% down from last year.
- According to the latest figures from Q3 2025, Vertex Pharmaceuticals' EPS (Weighted Average and Diluted) is $4.2, which was up 473.82% from $3.99 recorded in Q2 2025.
- Over the past 5 years, Vertex Pharmaceuticals' EPS (Weighted Average and Diluted) peaked at $4.21 during Q1 2024, and registered a low of -$13.92 during Q2 2024.
- Its 5-year average for EPS (Weighted Average and Diluted) is $2.33, with a median of $3.28 in 2021.
- As far as peak fluctuations go, Vertex Pharmaceuticals' EPS (Weighted Average and Diluted) skyrocketed by 110384.62% in 2022, and later tumbled by 49545.45% in 2024.
- Vertex Pharmaceuticals' EPS (Weighted Average and Diluted) (Quarter) stood at $2.96 in 2021, then rose by 5.97% to $3.14 in 2022, then rose by 18.44% to $3.72 in 2023, then dropped by 4.81% to $3.54 in 2024, then rose by 18.64% to $4.2 in 2025.
- Its EPS (Weighted Average and Diluted) stands at $4.2 for Q3 2025, versus $3.99 for Q2 2025 and $2.49 for Q1 2025.